18 June 2013
Keywords: gsk, faces, renewed, scrutiny, over, paxil, unsealed
Article | 23 June 2008
GlaxoSmithKline is under renewed scrutiny over its antidepressant Paxil (paroxetine HCl), after a US study suggested that the UK drug
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 June 2008
© 2013 thepharmaletter.com